Skip to main content
. 2014 Mar 9;2014(3):CD010062. doi: 10.1002/14651858.CD010062.pub2

ISRCTN66730162.

Study name Investigating the relationship between sleep disturbance and learning in children with Benign Epilepsy of Childhood with Centrotemporal Spikes (BECCTS): a randomised double blind placebo controlled crossover trial
Methods Randomised, double‐blind, placebo‐controlled, cross‐over trial. Six‐week treatment period (period A), followed by two‐week washout period, followed by six weeks of alternate treatment (period B)
Participants Inclusion criteria
  • Male and female children six to 16 years of age

  • Within six months of diagnosis with BECCTS and onset of symptoms

  • With clinical electroencephalographic (EEG) characteristics consistent with typical BECCTS

  • With no current or prior treatment for BECCTS

  • Signed informed (parental) consent


Exclusion criteria
  • Inability to comply with assessments

  • Any serious intercurrent illness or uncontrolled disease that could compromise participation in the study

  • With contraindications for treatment with sulthiame

    • History of hypersensitivity to sulphonamides

    • History of acute porphyria

    • History of hyperthyroidism

    • History of arterial hypertension

    • Impaired renal function

    • Psychiatric disorder

    • Hereditary galactose intolerance, Lapp lactase deficiency, glucose‐galactose malabsorption syndrome

Interventions Sulthiame versus placebo
Outcomes
  • Frequency of interictal epileptic discharges (IEDs) during slow wave sleep (SWS) on active treatment, relative to placebo, as measured by EEG at baseline, end of treatment period A and end of treatment period B

  • Sleep quality (efficiency, number of awakenings, density of sleep spindles and percentage rapid eye movement (REM) and percentage SWS on polysomnography) on active treatment relative to placebo, as measured at baseline, end of treatment period A and end of treatment period B

  • Performance on consolidation of learning (CoL) tasks on active treatment, relative to placebo, as measured (by validated CoL tools) at baseline, end of treatment period A and end of treatment period B

  • Performance on cognitive assessments including IQ and event‐related potential (ERP) utilising the commonly employed auditory oddball paradigm as a measure of basic sensory processing and attention, as measured at baseline, end of treatment period A and end of treatment period B

Starting date 13 July 2011
Contact information finbar.ocallaghan@bristol.ac.uk
Notes